Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial.
CONCLUSIONS: Long-term treatment with desvenlafaxine 50 mg/d maintained improvements in major depressive disorder among adult outpatients who exhibited a stable therapeutic response.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00887224.
PMID: 26693033 [PubMed] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - December 25, 2015 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research
A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d.
CONCLUSIONS: Desvenlafaxine significantly improved symptoms of depression versus placebo regardless of baseline BMI. In all BMI subgroups, desvenlafaxine was associated with statistically significant weight loss (< 1 kg) versus placebo over 8 weeks, but no significant differences longer term.
TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00072774, NCT00277823, NCT00300378, NCT00384033, NCT00798707, NCT00863798, NCT01121484, NCT00824291, NCT00887224.
PMID: 26644956 [PubMed - as supplied by publisher] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - December 12, 2015 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research
Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine.
Authors: Ghosh R, Gupta R, Bhatia MS, Tripathi AK, Gupta LK
Abstract
This randomized, open label, prospective, observational study compared clinical efficacy, safety alongwith plasma BDNF levels in outpatients of depression treated with fluoxetine and desvenlafaxine. Patients (aged 18-60 years) with moderate to severe major depressive disorder (MDD) diagnosed by DSM-IV criteria, and Hamilton Rating Scale for Depression (HAM-D) score ≥14, who were prescribed fluoxetine or desvenlafaxine were included (n=30 in each group). Patients were followed up for 12 weeks for evaluation of clinical efficacy, safety a...
Source: Asian Journal of Psychiatry - November 2, 2015 Category: Psychiatry Tags: Asian J Psychiatr Source Type: research
How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example.
CONCLUSIONS: A 2-step process based on FDA guidance can be used first to determine whether a pharmacokinetically mediated interaction occurs and then to assess the potential clinical significance of the DDI. In the case of the drug tested in this series of studies, the potential for clinically meaningful DDIs mediated by CYP 2D6, CYP 3A4, or P-gp was found to be low.
PMID: 26445693 [PubMed] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - October 9, 2015 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research
Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis
The primary objective of this post-hoc analysis was to evaluate the effect of short-term treatment with desvenlafaxine versus placebo on sexual dysfunction (SD), assessed from Arizona Sexual Experiences Scale scores, in adult outpatients with major depressive disorder. Data from three randomized, double-blind, placebo-controlled trials of 50 or 100 mg/day desvenlafaxine for major depressive disorder were pooled. SD status, determined from Arizona Sexual Experiences Scale scores, was assessed at baseline and week 8, last observation carried forward. Subgroup analyses addressed the effects of sex, baseline SD, and antidepr...
Source: International Clinical Psychopharmacology - October 1, 2015 Category: Psychiatry Tags: Original Articles Source Type: research
Reversal of corticosterone-induced BDNF alterations by the natural antioxidant alpha-lipoic acid alone and combined with desvenlafaxine: Emphasis on the neurotrophic hypothesis of depression
Brain derived neurotrophic factor (BDNF) is linked to the pathophysiology of depression. We hypothesized that BDNF is one of the neurobiological pathways related to the augmentation effect of alpha-lipoic acid (ALA) when associated with antidepressants. Female mice were administered vehicle or CORT 20mg/kg during 14 days. From the 15th to 21st days the animals were divided in groups that were further administered: vehicle, desvenlafaxine (DVS) 10 or 20mg/kg, ALA 100 or 200mg/kg or the combinations of DVS10+ALA100, DVS20+ALA100, DVS10+ALA200 or DVS20+ALA200. (Source: Psychiatry Research)
Source: Psychiatry Research - September 1, 2015 Category: Psychiatry Authors: Caren Nádia Soares de Sousa, Lucas Nascimento Meneses, Germana Silva Vasconcelos, Márcia Calheiros Chaves Silva, Jéssica Calheiros da Silva, Danielle Macêdo Gaspar, David Freitas de Lucena, Silvânia Maria Mendes Vasconcelos Source Type: research
Rapid and sensitive analysis of melatonin by LC-MS/MS and its application to pharmacokinetic study in dogs
Publication date: Available online 24 August 2015 Source:Asian Journal of Pharmaceutical Sciences Author(s): Huimin Zhao, Yifei Wang, Yi Jin, Shu Liu, Haiyan Xu, Xiumei Lu A rapid and sensitive liquid chromatography tandem mass spectrometry method was established and validated for determination of melatonin in dog plasma using desvenlafaxine as an internal standard (IS). Plasma samples were pretreated by liquid-liquid extraction with ethyl acetate. Chromatographic separation was carried out on a C18 column at a flow rate of 0.2 ml/min by an isocratic mobile phase of methanol: 5 mM ammonium acetate: formic a...
Source: Asian Journal of Pharmaceutical Sciences - August 26, 2015 Category: Drugs & Pharmacology Source Type: research
Evidence for protective effect of lipoic acid and desvenlafaxine on oxidative stress in a model depression in mice
Publication date: Available online 8 August 2015 Source:Progress in Neuro-Psychopharmacology and Biological Psychiatry Author(s): Márcia Calheiros Chaves Silva, Caren Nádia Soares de Sousa, Patrícia Xavier Lima Gomes, Gersilene Valente de Oliveira, Fernanda Yvelize Ramos Araújo, Naiara Coelho Ximenes, Jéssica Calheiros da Silva, Germana da Silva Vasconcelos, Luzia Kalyne Almeida Moreira Leal, Danielle Macêdo, Silvânia Maria Mendes Vasconcelos Oxidative stress is implicated in the neurobiology of depression. Here we investigated oxidative alterations in brain areas of animals submitted to th...
Source: Progress in Neuro Psychopharmacology and Biological Psychiatry - August 9, 2015 Category: Psychiatry Source Type: research
Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis.
CONCLUSIONS: There is no evidence that use of SNRIs is associated with a higher risk of hospitalization for AKI compared with SSRIs.
PMID: 26231193 [PubMed - as supplied by publisher] (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - July 31, 2015 Category: Urology & Nephrology Authors: Renoux C, Lix LM, Patenaude V, Bresee LC, Paterson JM, Lafrance JP, Tamim H, Mahmud SM, Alsabbagh MW, Hemmelgarn B, Dormuth CR, Ernst P, and the Canadian Network of Observational Drug Effect Studies (CNODES) Investigators Tags: Clin J Am Soc Nephrol Source Type: research
Desvenlafaxine for the Acute Treatment of Depression: A Systematic Review and Meta-analysis
Discussion: The risk ratios for response and remission were moderate. We further provide some evidence that desvenlafaxine might not be as efficacious as other antidepressants.[...]© Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals:Table of contents | Abstract | Full text (Source: Pharmacopsychiatry)
Source: Pharmacopsychiatry - July 23, 2015 Category: Psychiatry Authors: Laoutidis, Z. G.Kioulos, K. T. Tags: Review Source Type: research
Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder.
Conclusion: The overall incidence of any TPAE was lower in the taper versus abrupt discontinuation groups. Trial Registration: ClinicalTrials.gov identifier: NCT01056289.
PMID: 26137358 [PubMed - as supplied by publisher] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - July 3, 2015 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research
An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder.
Conclusions: Desvenlafaxine 50 to 400 mg/d effectively prevented relapse at 6 months. Desvenlafaxine significantly prevented relapse early (month 1) versus placebo only in study 2. Trial Registration: ClinicalTrials.gov identifiers:NCT00887224 and NCT00075257.
PMID: 26137355 [PubMed - as supplied by publisher] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - July 3, 2015 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research
Novel LC- ESI-MS/MS method for desvenlafaxine estimation human plasma:Application to pharmacokinetic study.
This article is protected by copyright. All rights reserved.
PMID: 26095112 [PubMed - as supplied by publisher] (Source: Biomedical Chromatography : BMC)
Source: Biomedical Chromatography : BMC - June 20, 2015 Category: Biomedical Science Authors: Pushpa Kumari K, Venu Gopal Raju K, Gowri Sankar D Tags: Biomed Chromatogr Source Type: research
In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.
Abstract
Desvenlafaxine is a biopharmaceutics classification system (BCS) class 1 (high solubility, high permeability) and biopharmaceutical drug disposition classification system (BDDCS) class 3, (high solubility, poor metabolism; implying low permeability) compound. Thus the rate-limiting step for desvenlafaxine absorption (i.e. intestinal dissolution or permeation) is not fully clarified. The aim of this study was to investigate whether dissolution and/or intestinal permeability rate-limit desvenlafaxine absorption from an immediate-release formulation (IRF) and Pristiq®, an extended release formulatio...
Source: European Journal of Pharmaceutical Sciences - June 16, 2015 Category: Drugs & Pharmacology Authors: Franek F, Jarlfors A, Larsen F, Holm P, Steffansen B Tags: Eur J Pharm Sci Source Type: research
Are SNRIs more effective than SSRIs? A review of the current state of the controversy.
Authors: Thase ME
Abstract
The selective serotonin reuptake inhibitors (SSRI) are widely considered to be the first choice for antidepressant therapy. There is evidence from inpatient studies dating to 1986, however, suggesting that the tricyclic antidepressant clomipramine, which inhibits reuptake of both serotonin and norepinephrine, may have greater efficacy than some SSRIs for severe depression. There is controversy whether the newer, better tolerated, and safer serotonin norepinephrine reuptake inhibitors (SNRIs; venlafaxine, duloxetine, and-in some countries-milnacipran and desvenlafaxine) are more e...
Source: Psychopharmacology Bulletin - June 5, 2015 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research
